By Colin Kellaher
Bluebird bio has struck a deal to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Bluebird on Friday said its investors will receive an initial $3 a share in cash under the deal, along with contingent value rights worth $6.84 a share that would be triggered if the gene-therapy company's current product portfolio achieves $600 million in sales in any trailing 12-month period by the end of 2027.
The potential total value of up to $9.84 a share represents a nearly 40% premium to Thursday's closing price of $7.04 for the Somerville, Mass., company.
The deal is slated to close in the first half of the year.
Trading in shares of bluebird was halted premarket on Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 21, 2025 07:59 ET (12:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。